Re: Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Open Access
Publisher Website
Google Scholar
Abstract
Tamoxifen reduces the development of invasive breast cancer in women at high risk for the disease (1). The Breast Cancer Prevention Trial (BCPT) demonstrated a 49% reduction of invasive breast cancer incidence in all high-risk women randomly assigned to receive tamoxifen and an even larger 86% reduction in invasive breast cancer incidence in women with cellular atypia of either the lobular or ductal type. Similarly, the International Breast Intervention Study I (IBIS I) trial showed a 33% reduction in the risk of developing invasive breast cancer among women randomly assigned to receive tamoxifen when compared with women taking placebo, regardless of their history of cellular atypia (2).